What early results did Epicrispr report for its EPI-321 gene silencer in FSHD?

Epicrispr Biotechnologies announced that its epigenetic editor EPI-321 increased lean muscle mass by an average of 0.8 pounds in three patients with facioscapulohumeral muscular dystrophy after a single IV infusion. The therapy works by silencing the Dux4 gene and showed no serious adverse events, marking the first reported muscle gain in an FSHD trial.